Jazz Pharmaceuticals (JAZZ) | Stock Overview & Key Data
Jazz Pharmaceuticals Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $243.32 on May 22, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jazz Pharmaceuticals
JAZZ
|
12.31B Large-cap | -0.62% | 0.80% | 26.68% | 36.02% | 33.17% | 112.50% | 79.15% | 30.05% | 60.52% | 688.78% | 1,200.39% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Alnylam
ALNY
|
41.87B Large-cap | -1.49% | 0.29% | -9.76% | -26.49% | -28.08% | -8.16% | 40.32% | 59.90% | 405.36% | 3,032.34% | 1,907.45% |
|
Insmed
INSM
|
31.05B Large-cap | 3.49% | -10.70% | -32.60% | -50.51% | -44.98% | -0.89% | 389.25% | 236.25% | 934.36% | 717.46% | 614.23% |
|
Revolution Medicines
RVMD
|
28.61B Large-cap | 7.79% | 9.89% | 61.68% | 102.61% | 102.56% | 279.08% | 524.98% | 353.09% | 443.52% | 443.52% | 443.52% |
Ownership & Short Interest
Calculate Your Jazz Pharmaceuticals Investment Returns
Long-Term Investment Performance Analysis
Jazz Pharmaceuticals stock price in Jul 2016 was $141.96, A $1,000.00 lump sum investment in Jazz Pharmaceuticals made 9 years ago would be worth approximately $1,624.33 today, representing a solid return of 62.43%. This translates to an annualized return (CAGR) of 5.02%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is JAZZ's 52-week high and low?
- In the last 52 weeks, Jazz Pharmaceuticals reached a high of $243.32 (on May 22, 2026) and a low of $105.00 (on August 6, 2025).
- What is the market cap and P/E ratio for JAZZ?
- Curious about Jazz Pharmaceuticals's size and valuation? Its market capitalization stands at 12.31B. When it comes to valuation, the P/E ratio (trailing twelve months) is 14.39, and the forward P/E (looking ahead) is 7.95.
- Does JAZZ pay dividends? If so, what's the yield?
- As for dividends, Jazz Pharmaceuticals isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Jazz Pharmaceuticals's main competitors or similar companies to consider before investing?
When looking at Jazz Pharmaceuticals, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Alnylam
ALNY41.87B Healthcare Biotechnology -8.16% 40.32% Insmed
INSM31.05B Healthcare Biotechnology -0.89% 389.25% Revolution Medicines
RVMD28.61B Healthcare Biotechnology 279.08% 524.98% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Jazz Pharmaceuticals plc? (e.g., ROE, Debt/Equity)
- To get a sense of Jazz Pharmaceuticals's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -8.47%, the Debt to Equity ratio from the most recent quarter is 125.67, and its Gross Profit Margin stands at 87.18%.
- What is the recent revenue and earnings growth for JAZZ?
- Looking at Jazz Pharmaceuticals's growth, its revenue over the trailing twelve months (TTM) was $4B. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.10%, and quarterly earnings saw a YoY growth of 6.50%.
- How much of JAZZ stock is held by insiders and institutions?
- Wondering who owns Jazz Pharmaceuticals stock? Company insiders (like executives and directors) hold about 3.08% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 104.66%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.